Pildu Jeong

Pildu Jeong

Auto-generated profile, based on publicly available information

Pildu Jeong

Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2004 in Urology
Verified
Journal Article
Closed access
PDF file
PJPildu Jeong
Pildu Jeong
EKEun-Jung Kim
Eun-Jung Kim
EKEung-Gook Kim
Eung-Gook Kim
SBSeok-Soo Byun
Seok-Soo Byun
CKChoung-Soo Kim
Choung-Soo Kim
WKWun-Jae Kim
Wun-Jae Kim

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YKYe-Hwan Kim
Ye-Hwan Kim
WKWon Tae Kim
Won Tae Kim
PJPildu Jeong
Pildu Jeong
YHYun-Sok Ha
Yun-Sok Ha
HKHo Won Kang
Ho Won Kang
WKWun-Jae Kim
Wun-Jae Kim
Kim YH, et al. J Korean Med Sci. 2014 Mar;29(3):351-356. https://doi.org/10.3346/jkms.2014.29.3.351

1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
YKYe-Hwan Kim
Ye-Hwan Kim
YBYoung Joon Byun
Young Joon Byun
WKWon Tae Kim
Won Tae Kim
PJPildu Jeong
Pildu Jeong
CYChunri Yan
Chunri Yan
WKWun-Jae Kim
Wun-Jae Kim
Kim YH, et al. J Korean Med Sci. 2018 Oct;33(47):e303. https://doi.org/10.3346/jkms.2018.33.e303

1 January 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
YBYoung Joon Byun
Young Joon Byun
XPXuan-Mei Piao
Xuan-Mei Piao
PJPildu Jeong
Pildu Jeong
HKHo Won Kang
Ho Won Kang
SSSung Phil Seo
Sung Phil Seo
WKWun-Jae Kim
Wun-Jae Kim
Byun YJ, et al. Investig Clin Urol. 2021 May;62(3):340-348. https://doi.org/10.4111/icu.20200488

30 June 2016 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
SYSeok Joong Yun
Seok Joong Yun
PJPildu Jeong
Pildu Jeong
HKHo Won Kang
Ho Won Kang
HSHelen Ki Shinn
Helen Ki Shinn
YKYe-Hwan Kim
Ye-Hwan Kim
WKWun-Jae Kim
Wun-Jae Kim
Previously, we reported the presence of virus-encoded microRNAs (miRNAs) in the urine of prostate cancer (CaP) patients. In this study, we investigated the expression of two herpes virus-encoded miRNAs in prostate tissue. A total of 175 tissue samples from noncancerous benign prostatic hyperplasia (BPH), 248 tissue samples from patients with CaP and BPH, and 50 samples from noncancerous surrounding tissues from these same patients were analyzed for the expression of two herpes virus-encoded miRNAs by real-time polymerase chain reaction (PCR) and immunocytochemistry using nanoparticles as molecular beacons. Real-time reverse transcription-PCR results revealed significantly higher expression of hsv1-miR-H18 and hsv2-miRH9- 5p in surrounding noncancerous and CaP tissues than that in BPH tissue (each comparison, P<0.001). Of note, these miRNA were expressed equivalently in the CaP tissues and surrounding noncancerous tissues. Moreover, immunocytochemistry clearly demonstrated a significant enrichment of both hsv1-miR-H18 and hsv2-miR-H9 beacon-labeled cells in CaP and surrounding noncancerous tissue compared to that in BPH tissue (each comparison, P<0.05 for hsv1-miR-H18 and hsv2- miR-H9). These results suggest that increased expression of hsv1-miR-H18 and hsv2-miR-H95p might be associated with tumorigenesis in the prostate. Further studies will be required to elucidate the role of these miRNAs with respect to CaP and herpes viral infections.

1 July 2020 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
HKHo Won Kang
Ho Won Kang
HLHee Youn Lee
Hee Youn Lee
YBYoung Joon Byun
Young Joon Byun
PJPildu Jeong
Pildu Jeong
JYJin Sun Yoon
Jin Sun Yoon
WKWun-Jae Kim
Wun-Jae Kim
Purpose: The aim of this study was to identify a noninvasive urinary marker for prostate cancer (PCa) diagnosis and to validate the clinical performance of this novel urinary mRNA signature using the droplet digital polymerase chain reaction (ddPCR) approach. Materials and Methods: A gene expression microarray (HT-12, Illumina Inc., USA) was used to identify genes differentially expressed between 16 PCa and 8 benign prostatic hyperplasia (BPH) tissues; ddPCR (QX200; Bio-Rad Laboratories, USA) was carried out to quantify the expression of selected genes in urine. The urinary molecular PCa risk score (UMPCaRS) was calculated by using the sum of three upregulated genes as the numerator and the sum of three downregulated genes as the denominator. The diagnostic utility of the UMPCaRS was validated by using a screening set (10 PCa and 10 BPH samples) and a validation set (131 PCa and 105 BPH samples). Results: Three upregulated genes (PDLIMS, GDF-1 5, THBS4) and three downregulated genes (UPK1A, SSTR3, NPFFR2) were selected from the microarray and subjected to ddPCR. The UMPCaRS for PCa in the screening and validation sets was significantly higher than that for BPH. For the validation set, the diagnostic accuracy of the UMPCaRS was comparable with that of prostate-specific antigen (PSA). Importantly, in the "PSA gray zone" (3-10 ng/mL), the AUC for the UMPCaRS was 0.843 and that for PSA was 0.628 (p<0.001). Conclusions: The data demonstrate that the UM PCaRS is useful for discriminating between PCa and BPH in the "PSA gray zone".